Orchestra BioMed Holdings (OBIO) Cash from Financing Activities (2022 - 2026)
Orchestra BioMed Holdings (OBIO) reported Cash from Financing Activities of $5.5 million for Q1 2026, up 1967.23% year-over-year from $267362.6 in Q1 2025, and down 56.34% on a QoQ basis from $12.7 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 5 years of Cash from Financing Activities data on file, last reported at $5.5 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 1967.23% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.2 million (up 226.28% YoY) and the FY2025 annual result came in at $88.3 million, up 202.81% from the prior year.
- Cash from Financing Activities slipped to $5.5 million in Q1 2026 per OBIO's latest filing, from $12.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $86.1 million in Q2 2022 and bottomed at -$10.7 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is $171000.0 (2024), against an average of $16.0 million.
- The widest annual swing landed in 2024, when Cash from Financing Activities jumped 375775.0%; it then slumped 1744.44% in 2025.
- Tracing OBIO's Cash from Financing Activities over 5 years: stood at -$5.1 million in 2022, then plunged by 110.14% to -$10.7 million in 2023, then surged by 230.39% to $13.9 million in 2024, then slipped by 9.23% to $12.7 million in 2025, then slumped by 56.34% to $5.5 million in 2026.
- Per Business Quant, the three latest OBIO Cash from Financing Activities figures stand at $5.5 million (Q1 2026), $12.7 million (Q4 2025), and $76.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | 5.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.53 Mn |
| Mar 31, 2026 | 5.53 Mn |
| Dec 31, 2025 | 12.66 Mn |
| Dec 31, 2025 | 12.66 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Jun 30, 2025 | -428,000.00 |
| Jun 30, 2025 | -428,000.00 |
| Mar 31, 2025 | -296,000.00 |
| Mar 31, 2025 | -296,000.00 |
| Dec 31, 2024 | 13.95 Mn |
| Dec 31, 2024 | 13.95 Mn |
| Sep 30, 2024 | 15.04 Mn |
| Sep 30, 2024 | 15.04 Mn |
| Jun 30, 2024 | 171,000.00 |
| Jun 30, 2024 | 171,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Dec 31, 2023 | -10.70 Mn |
| Dec 31, 2023 | -10.70 Mn |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Mar 31, 2023 | 56.82 Mn |
| Mar 31, 2023 | 56.82 Mn |
| Dec 31, 2022 | -5.09 Mn |
| Dec 31, 2022 | -5.09 Mn |
| Sep 30, 2022 | -2.50 Mn |
| Sep 30, 2022 | -2.50 Mn |
| Jun 30, 2022 | 86.08 Mn |
| Jun 30, 2022 | 86.08 Mn |
| Mar 31, 2022 | 24.76 Mn |
| Mar 31, 2022 | 24.76 Mn |